Cost of illness of Crohn's disease

PharmacoEconomics

Volumn 20, Issue 10, 2002, Pages 639-652

  Bodger, Keith ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; MESALAZINE; METRONIDAZOLE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ABSENTEEISM; BLOOD TOXICITY; CHRONIC INFLAMMATION; CHRONICITY; COST OF ILLNESS; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; EUROPE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; ONSET AGE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RASH; REMISSION; REVIEW; UNITED KINGDOM;

EID: 0036373358     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220100-00001     Document Type: Review

References (64)

1. Clinical economics in gastroenterology
2. Clinical presentations
3. Epidemiology of inflammatory bowel disease
4. An epidemiologic study of inflammatory bowel disease in Rochester, New York
5. Epidemiological aspects of inflammatory bowel disease in a north Italian population: A 4 year prospective study
6. Incidence of ulcerative colitis in Cardiff over 20 years: 1968-87
7. Incidence of inflammatory bowel disease in northern France (1988-1990)
8. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: A sixfold increase in incidence
9. Epidemiology of inflammatory bowel disease
10. Update on the epidemiology of IBD
11. Inflammatory bowel disease: Epidemiology and management in an English general practice population
12. Clinical course and costs of care for Crohn's disease: Markov Model Analysis of a population-based cohort
13. Inflammatory bowel disease management
14. Inflammatory bowel disease: Current concepts in pathogenesis and therapy
15. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease
16. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease
17. Surgical therapy for ulcerative colitis and Chron's disease
18. New biotechnological therapies for Crohn's disease: Where are we now?
19. Inflammatory bowel disease: Health care and costs in Sweden in 1994
20. Economic impact of inflammatory bowel disease in Alberta
21. Inflammatory bowel disease: Costs-of-illness
22. The relationship between Insurance class and severity of presentation of inflammatory bowel disease in children
23. Annual cost of care for Crohn's disease: A Payor Perspective
24. Direct hospital costs for patients with inflammatory bowel disease in a Canadian Tertiary care university hospital
25. The cost of hospitalisation in Crohn's disease
26. Inflammatory bowel disease: Medical cost algorithms
27. National Co-operative Crohn's Disease Study: Results of drug treatment
28. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
29. 5-Amino-salicylle acid in the treatment of Crohn's disease: A 16-week double-blind, placebo-controlled, multicentre study with Pentasa
30. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
31. Oral budesonide for active Crohn's disease
32. Double blind, placebo controlled trial of metronidazole in Crohn's disease
33. Second trial of mesalamine therapy in the treatment of active Crohn's disease
34. Oral 5 aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease
35. Clinical efficacy of oral mesalazine in Crohn's disease
36. Oral 5-ASA versus prednisone in short term treatment of Crohn's disease: A multicentre controlled trial
37. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial
38. A comparison of budesonide with prednisolone for active Crohn's disease
39. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin
40. Healing of perianal Crohn's disease with metronidazole
41. Azathioprine for Crohn's disease
42. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease
43. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease
44. Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients
45. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
46. Drug treatments for maintaining remission in Crohn's disease: A lifetime cost-utility analysis
47. Azathioprine for maintaining remission of Crohn's disease
48. A 10-year survey of inflammatory bowel diseases - Drug therapy, costs and adverse reactions
49. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials
50. Nutritional support: Efficacy and cost-effectiveness
51. Analysing hospital costs for patients with inflammatory bowel disease
52. The health care economic implications of minimal access gastrointestinal surgery
53. Place of laparoscopic surgery in Crohn's disease
54. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2)
55. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease
56. Cost-utility of initial medical management for Crohn's disease perianal fistulae
57. Review article: Economic issues in Crohn's disease - Assessing effects of new treatments on health-related quality of life
58. Inflammatory bowel disease; Patient expectations in the 1990's
59. Life insurance and inflammatory bowel disease: Is there discrimination against patients?
60. Insurance rating of patients with inflammatory bowel disease: Report of a conference on morbidity and mortality
61. Clinical economics review: Medical management of inflammatory bowel disease
62. Disability from inflammatory bowel disease among employees in West Germany
63. Disability and need for rehabilitation among patients with inflammatory bowel disease